Interview: Amryt Aims High After Aegerion Acquisition
Executive Summary
The Irish firm's CEO told Scrip about a transformative deal for Amryt, creating an international business with revenues of nearly $140m.
You may also be interested in...
Amryt Predicts $1bn Revenues After Chiasma Acquisition
The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.
Amryt Flies As Butterfly Skin Therapy Hits Late-Stage Goal
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
Syncona Biotechs Face Up To Trial Delays Over COVID-19
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.